Atherosclerosis and cardiovascular disease

The disease develops in the arterial wall

Arteries deliver blood from the heart to tissues. Their endothelial lining does more than separate blood from the wall: it influences vascular tone, movement of substances, and interactions with platelets and white cells. Atherosclerosis mainly involves the intima of medium and large arteries, rather than a floating layer of oil in blood. Cholesterol is a necessary molecule transported in lipoproteins; the problem involves sustained entry and retention of relevant particles within susceptible arterial regions. LDL and other apolipoprotein B-containing particles contribute to this process. Endothelial changes, local flow patterns, and exposure over time influence where lesions develop. A blood lipid result describes circulating concentrations, not the condition of every arterial wall. High LDL cholesterol calls for risk assessment but does not diagnose a completely blocked artery. Conversely, one unremarkable measurement cannot erase accumulated exposure or established disease. Time and location belong in the explanation.

Sources: NHLBI: What is atherosclerosis; NHLBI: Causes and risk factors; Mechanisms of Vascular Disease: Atherosclerosis; NHLBI: Blood cholesterol

Lipids, immune cells, and fibrous tissue build a plaque

Modified retained lipoproteins participate in local inflammation. Monocytes enter the wall and differentiate into macrophages; lipid uptake creates foam cells, and other cells can accumulate lipid too. Continued deposition, cell death, and inadequate clearance can produce a region containing lipid and cellular debris. This is an interaction over time, not a single fatty meal instantly becoming a plaque. Smooth muscle cells contribute through migration, proliferation, and production of collagen and other extracellular matrix. A fibrous cap can separate deeper thrombogenic material from circulating blood, and calcification may also occur. A plaque is thus a complex lesion involving lipid, cells, and supporting tissue, not loose material that a drink can wash away. Composition and rate of change differ among lesions, including within one person. The sequence is a mechanistic guide rather than a timetable requiring every fatty streak to progress to an acute clinical event.

Sources: Mechanisms of Vascular Disease: Atherosclerosis; StatPearls: Atherosclerosis

Gradual narrowing and sudden thrombosis differ

Plaque growth can narrow the lumen, but the arterial wall can also remodel outward, so wall disease and measured narrowing need not advance in parallel. When narrowing restricts the increase in blood flow needed during activity, tissue demand can exceed supply. In coronary arteries, this may contribute to exertional chest discomfort, although symptoms require clinical interpretation. Another pathway involves plaque rupture or surface erosion, followed by platelet activation and coagulation. A thrombus can then reduce or interrupt flow abruptly. An acute event is therefore not simply the previously narrowest point finally closing. Composition, surface changes, and the clotting response matter as well. A stenosis percentage alone cannot establish either zero risk or an imminent event. A procedure restoring flow at one location also does not remove all disease elsewhere. These mechanisms explain why treatment of a particular lesion and continuing management of overall risk serve complementary purposes.

Sources: NHLBI: Atherosclerosis symptoms; Mechanisms of Vascular Disease: Atherosclerosis; StatPearls: Atherosclerosis; NHLBI: Atherosclerosis treatment

The organ shapes symptoms, and emergencies need action

Coronary involvement affects the heart, disease in arteries supplying the brain can contribute to ischaemic stroke, and leg-artery disease may produce walking-related pain relieved by rest. Several territories can be involved at once, so absence of chest pain does not establish absence of risk elsewhere. Not every heart condition or stroke arises from atherosclerosis: strokes can also involve emboli from the heart or bleeding, among other causes. Chest pressure or discomfort with breathlessness, sweating, or nausea may indicate myocardial infarction, and symptoms are not always dramatic. Suspected heart attack requires an immediate emergency call rather than waiting for deterioration. Sudden facial droop, unilateral arm weakness, or speech difficulty calls for immediate emergency assistance; sudden vision or balance changes can also signal stroke. Note onset or the last known normal time, and do not drive yourself. Symptoms that resolve still require urgent assessment. Do not self-treat suspected stroke with aspirin on the assumption of a clot, because bleeding and ischaemic stroke must be distinguished.

Sources: NHLBI: Atherosclerosis symptoms; CDC: Stroke signs and symptoms; NHLBI: Heart attack symptoms; AHA: Aspirin and dual antiplatelet therapy

Risk assessment integrates exposures without predicting destiny

Age, family history, LDL cholesterol, smoking, blood pressure, and diabetes influence cardiovascular risk. Assessment brings these together to inform prevention rather than labelling an individual as destined to have an event. A younger person may have low short-term absolute risk while prolonged exposure remains relevant. Increasing age-related risk likewise does not make modifiable factors irrelevant. Investigations should answer defined questions. Lipids and blood pressure assess exposures; imaging can examine plaque or the lumen; functional investigations explore supply relative to demand. Coronary calcium scoring can help selected decisions in selected people, but it is not compulsory screening for everyone and does not independently establish the stability of each plaque. Ask how a result would change management, what burdens the investigation carries, and what a normal finding could leave uncertain. Any numerical estimate needs a time horizon and an appropriate population, and remains an estimate rather than a personal forecast.

Sources: NHLBI: Causes and risk factors; NHLBI: Atherosclerosis diagnosis

Reducing events matters more than promising plaque clearance

Long-term management aims to reduce further injury and clinical events. It includes smoking cessation, appropriate activity, a heart-supportive dietary pattern, and clinically guided management of lipids, blood pressure, and diabetes. Lipid-lowering medication reduces relevant exposure, and some treatments can modify plaque progression. Decisions depend on established disease, overall risk, expected benefit, and adverse effects rather than one universal online threshold. Antiplatelet treatment has roles in particular diagnosed cardiovascular settings but increases bleeding risk; not everyone seeking to prevent a heart attack should take it, and it should not be started without clinical advice. Revascularization can address selected flow problems, while continuing risk management remains necessary afterwards. Someone who receives a stent and then resumes smoking and stops all medication has confused local flow improvement with resolution of systemic disease. Reducing events, preserving function, and sustaining a workable plan are more meaningful goals than promises to reverse vascular age or remove every plaque with a particular drink.

Sources: NHLBI: Atherosclerosis treatment; AHA: Aspirin and dual antiplatelet therapy

Bilingual terms

内皮 · Endothelium

The vessel-lining cell layer involved in vascular and clotting regulation.

泡沫细胞 · Foam cell

A lipid-laden cell, often a macrophage, within a lesion.

纤维帽 · Fibrous cap

Collagen-rich tissue covering deeper plaque material.

血栓 · Thrombus

A clot formed within a vessel or cardiac chamber.

缺血 · Ischaemia

Blood supply inadequate for tissue needs.

血管重塑 · Vascular remodelling

Changes in vessel-wall structure and dimensions over time.

Sources and further reading

• NHLBI: What is atherosclerosis
• NHLBI: Causes and risk factors
• NHLBI: Atherosclerosis treatment
• NHLBI: Atherosclerosis symptoms
• Mechanisms of Vascular Disease: Atherosclerosis
• CDC: Stroke signs and symptoms
• NHLBI: Heart attack symptoms
• NHLBI: Atherosclerosis diagnosis
• NHLBI: Blood cholesterol
• StatPearls: Atherosclerosis
• AHA: Aspirin and dual antiplatelet therapy

Original course source-check record: 9 September 2026. Full Chinese and English sentence-by-sentence language review: 14 September 2026. AI editing and language review are not human clinical review. Linked institutions have not participated in or endorsed this course.